Sign In
Buy ETON
$27.61
+0.210 (+0.766%)
At Close: Jun 03, 2026
What Makes Eton Pharmaceuticals (ETON) a Good Fit for 'Trend Investing'
09:50am, Monday, 18'th Nov 2024
Eton Pharmaceuticals (ETON) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed t
Eton Pharmaceuticals, Inc. (ETON) Q3 2024 Earnings Call Transcript
08:01pm, Tuesday, 12'th Nov 2024
Eton Pharmaceuticals, Inc. (NASDAQ:ETON ) Q3 2024 Earnings Conference Call November 12, 2024 4:30 PM ET Company Participants David Krempa – Chief Business Officer Sean Brynjelsen – Chief Executive
Eton Pharmaceuticals Reports Third Quarter 2024 Financial Results
04:01pm, Tuesday, 12'th Nov 2024
DEER PARK, Ill., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or “the Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercial
Eton Pharmaceuticals to Report Third Quarter 2024 Financial Results on Tuesday, November 12, 2024
04:30pm, Wednesday, 06'th Nov 2024
DEER PARK, Ill., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc. (“Eton” or the "Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commerciali
Eton Pharmaceuticals, Inc to Acquire Increlex® (mecasermin injection) from Ipsen
06:30am, Thursday, 03'rd Oct 2024
Aligns with Eton's Mission to Develop and Distribute Medicines that Have a Life Changing Impact for Patients with Ultra-rare Conditions
Eton Pharmaceuticals to Participate at the H.C. Wainwright 26th Annual Global Investment Conference
04:30pm, Thursday, 22'nd Aug 2024
DEER PARK, Ill., Aug. 22, 2024 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or the “Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercial
Eton Pharmaceuticals, Inc. (ETON) Q2 2024 Earnings Call Transcript
08:15am, Sunday, 11'th Aug 2024
Eton Pharmaceuticals, Inc. (NASDAQ:ETON ) Q2 2024 Earnings Conference Call August 8, 2024 4:30 PM ET Company Participants David Krempa - Chief Business Officer Sean Brynjelsen - Chief Executive Office
Eton Pharmaceuticals Reports Second Quarter 2024 Financial Results
04:01pm, Thursday, 08'th Aug 2024
DEER PARK, Ill., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or “the Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercial
Eton Pharmaceuticals to Report Second Quarter 2024 Financial Results on Thursday, August 8, 2024
05:30pm, Tuesday, 30'th Jul 2024
DEER PARK, Ill., July 30, 2024 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc. (“Eton” or the "Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commerciali
Eton Pharmaceuticals Announces FDA Acceptance of New Drug Application for ET-400 (Hydrocortisone Oral Solution)
04:05pm, Monday, 15'th Jul 2024
- Prescription Drug User Fee Act (PDUFA) target action date is February 28, 2025 - - Product has patent protection through 2043 - DEER PARK, Ill., July 15, 2024 (GLOBE NEWSWIRE) -- Eton Pharmaceutical
Eton Pharmaceuticals, Inc. Q1 2024 Earnings Call Transcript
09:34am, Saturday, 11'th May 2024
Eton Pharmaceuticals, Inc. Q1 2024 Earnings Call Transcript May 9, 2024 4:30 PM ET Company Participants David Krempa - Chief Business Officer Sean Brynjelsen - Chief Executive Officer James Gruber - C
Eton Pharmaceuticals Reports First Quarter 2024 Financial Results
04:01pm, Thursday, 09'th May 2024
• Q1 2024 revenue of $8.0 million, representing 50% growth over Q1 2023 and the 13th straight quarter of sequential product sales growth• Acquired PKU GOLIKE®, launched Nitisinone, and subm
Eton Pharmaceuticals to Present at the Citizens JMP Life Sciences Conference
04:05pm, Wednesday, 01'st May 2024
DEER PARK, Ill., May 01, 2024 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases,
Eton Pharmaceuticals Announces Submission to FDA of New Drug Application for ET-400 (Hydrocortisone Oral Solution)
07:00am, Tuesday, 30'th Apr 2024
- Company anticipates 10-month review for potential approval in Q1 2025 -- Eton expects ET-400 and Alkindi Sprinkle® to achieve potential combined peak sales of more than $50 million annually -- Prod
Eton Pharmaceuticals to Report First Quarter 2024 Financial Results on Thursday, May 9, 2024
04:30pm, Monday, 29'th Apr 2024
DEER PARK, Ill., April 29, 2024 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc. (“Eton” or the "Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercial
